Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Breast Cancer Tumors Grow Faster in Younger Women

By HospiMedica staff writers
Posted on 20 May 2008
A new study shows that tumor growth rates vary considerably among patients, with generally slower growth rates with increasing age at diagnosis. More...


Researchers at the Cancer Registry of Norway (Oslo) developed a likelihood based estimating procedure, where both tumor growth and screen test sensitivity (STS) were modeled as continuously increasing functions of tumor size. The estimating procedure to follow tumor growth was based on breast screening results from 395,188 women aged between 50 and 69 years old included in the Norwegian breast cancer screening program.

The researchers found that tumor growth varied considerably between subjects, with 5% of tumors needing less than 1.2 months to grow from 10 to 20 mm in diameter, and another 5% using more than 6.3 years. The mean time a tumor needed to grow from 10 to 20 mm in diameter was estimated at1.7 years, increasing with age. STS was estimated to increase sharply with tumor size, going from 26 % at 5 mm to 91 % at 10 mm. Compared to previously used Markov models for tumor progression, the applied model gave considerably higher model fit (85 % increased predictive power) and provided estimates directly linked to tumor size. The study was published online on May 8, 2008, in Breast Cancer Research, a publication of BioMed Central (www.biomedcentral.com).

"There are enormous implications for the sensitivity of breast cancer screening programs,” said Harald Weedon-Fekjær, a statistician the department of etiological research. "We found that mammography screen test sensitivity (STS) increases sharply with increased tumor size, as one might expect. Detection rates are just 26% for a 5 mm tumor but increase to 91% once a tumor is 10 mm in size.”

The study also describes a new model for estimating the proportion of breast cancers, which are detected at screening, and the ability of mammography screening to detect tumors.


Related Links:
Cancer Registry of Norway
BioMed Central

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
LED Surgical Lamp
ACEMST35/57
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.